Compare STBA & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STBA | WGS |
|---|---|---|
| Founded | 1902 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Major Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.0B |
| IPO Year | 1995 | N/A |
| Metric | STBA | WGS |
|---|---|---|
| Price | $43.80 | $58.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $43.00 | ★ $130.71 |
| AVG Volume (30 Days) | 197.9K | ★ 661.5K |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | ★ 2.35 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.20 | $29.98 |
| Revenue Next Year | $4.14 | $25.92 |
| P/E Ratio | ★ $12.76 | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.45 | $55.17 |
| 52 Week High | $44.91 | $170.87 |
| Indicator | STBA | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 33.00 |
| Support Level | $42.08 | $55.18 |
| Resistance Level | $44.86 | $95.75 |
| Average True Range (ATR) | 0.89 | 4.26 |
| MACD | 0.40 | 0.25 |
| Stochastic Oscillator | 79.22 | 16.20 |
S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. It operates only in one segment which is Community Banking. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.